Daiwa Securities Group
NRIX icon

Daiwa Securities Group’s Nurix Therapeutics NRIX Stock Holding History

Daiwa Securities Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-338
Closed -$6K – 1354
2025
Q4 		$6K Buy
338
+93
+38% +$1.34K ﹤0.01% 1223
2025
Q3 		$2K Hold
245
– – ﹤0.01% 1277
2025
Q2 		$3K Hold
245
– – ﹤0.01% 1194
2025
Q1 		$3K Hold
245
– – ﹤0.01% 1167
2024
Q4 		$5K Hold
245
– – ﹤0.01% 1163
2024
Q3 		$6K Buy
245
+93
+61% +$2.11K ﹤0.01% 1160
2024
Q2 		$3K Hold
152
– – ﹤0.01% 1232
2024
Q1 		$2K Hold
152
– – ﹤0.01% 1273
2023
Q4 		$2K Hold
152
– – ﹤0.01% 1276
2023
Q3 		$1K Hold
152
– – ﹤0.01% 1266
2023
Q2 		$2K Hold
152
– – ﹤0.01% 1239
2023
Q1 		$1K Hold
152
– – ﹤0.01% 1268
2022
Q4 		$2K Hold
152
– – ﹤0.01% 1232
2022
Q3 		$2K Hold
152
– – ﹤0.01% 1241
2022
Q2 		$2K Hold
152
– – ﹤0.01% 1248
2022
Q1 		$2K Hold
152
– – ﹤0.01% 1264
2021
Q4 		$4K Hold
152
– – ﹤0.01% 1223
2021
Q3 		$5K Buy
152
+79
+108% +$2.44K ﹤0.01% 1178
2021
Q2 		$2K Hold
73
– – ﹤0.01% 1146
2021
Q1 		$2K Hold
73
– – ﹤0.01% 1149
2020
Q4 		$2K Buy
+73
New +$2.42K ﹤0.01% 1128

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Daiwa Securities Group's NRIX Position: Q1 2026 in Review

Daiwa Securities Group sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 338 shares — an estimated $6K sold.

Daiwa Securities Group first reported a position in NRIX in Q4 2020 and held it in 21 quarters. The position peaked at $6K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Daiwa Securities Group reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 338 Nurix Therapeutics shares in Q1 2026, an estimated $6K.
  • Daiwa Securities Group first reported a position in Nurix Therapeutics in Q4 2020 and held it in 21 quarters.
  • Daiwa Securities Group's Nurix Therapeutics position peaked at $6K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.